Gewinn- und Verlustrechnung von MetLife, Inc.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has declared a fourth quarter 2026 common stock dividend of $0.5925 per share. The dividend will be payable on December 8, 2026, to shareholders of record as of November 3, 2026. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset managemen.

Michael Burry (Trades, Portfolio) is positioning several U.S. stock holdings around the year-end tax-loss selling period, while using option trades and portfoli

Argent Capital Management LLC purchased a new stake in MetLife, Inc. (NYSE: MET) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 121,303 shares of the financial services provider's stock, valued at approximately $11,422,000. Several other hedge funds have also modified their

MET's Group Benefits earnings jump 25% in Q2 2026, fueled by stronger underwriting and demand, but some mortality gains may fade.

Life insurers generally benefit from higher rates, but there are some negatives to consider.

Record annuity demand creates opportunities for Prudential, Principal Financial and MetLife as retirement needs and pension solutions grow.

MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the close of Galaxy 38 CLO, Ltd.

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the close of Galaxy 38 CLO, Ltd. (Galaxy 38), a $450 million target par new issue collateralized loan obligation (CLO). PineBridge Investments, which is part of MIM, serves as collateral manager for the transaction. BofA Securities, Inc. acted as arranger. Galaxy 38 marks the 45th CLO issuance by the Leveraged Finance team, building on t.

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a

MetLife (NYSE: MET - Get Free Report) and Global Indemnity Group (NASDAQ: GBLI - Get Free Report) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Valuation and Earnings This table compares MetLife and